HOSPITAL UNIVERSITARIO RUBER
Department
Yale Cancer Center
New Haven, Estados UnidosPublications in collaboration with researchers from Yale Cancer Center (4)
2023
-
ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
Molecular Oncology, Vol. 17, Núm. 10, pp. 2000-2016
-
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
Genome Medicine, Vol. 15, Núm. 1
-
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
JAMA Oncology, Vol. 9, Núm. 4, pp. 490-499
2022
-
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations
JAMA Oncology, Vol. 8, Núm. 11, pp. 1668-1675